Abstracts tagged "Adalimumab and spondylarthropathy"

Abstract Number: 570 • 2012 ACR/ARHP Annual Meeting
Randomized Controlled Trial of Adalimumab in Patients with Peripheral Spondyloarthritis
Philip J. Mease¹, Joachim Sieper², Filip Van den Bosch³, Proton Rahman⁴, Katie Obermeyer⁵ and Aileen L. Pangan⁵, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, ³Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁴Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁵Abbott Laboratories, Abbott Park, IL
Background/Purpose: Adalimumab (ADA) is indicated for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Patients (pts) with peripheral spondyloarthritis (SpA) not previously diagnosed…
Abstract Number: 2214 • 2012 ACR/ARHP Annual Meeting
Similar Levels of Disease Activity in Patients with Oligoarticular Vs. Polyarticular Peripheral Spondyloarthritis
Filip Van den Bosch¹, Philip J. Mease², Désirée van der Heijde³, Martin Rudwaleit⁴, Katie Obermeyer⁵ and Aileen L. Pangan⁵, ¹Ghent University Hospital, Ghent, Belgium, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Endokrinologikum Berlin, Berlin, Germany, ⁵Abbott Laboratories, Abbott Park, IL
Background/Purpose: The ASAS criteria for peripheral spondyloarthritis (SpA) allow for classification of patients with SpA who present with peripheral arthritis, enthesitis and/or dactylitis.1 ABILITY-2, a…